Cardlytics Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Cardlytics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CDLX, but not buy additional shares or sell existing shares.
View analyst ratings for Cardlytics or view top-rated stocks.

Wall Street analysts have given Cardlytics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cardlytics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Cardlytics is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Cardlytics.

Cardlytics, Inc. (NASDAQ:CDLX) posted its earnings results on Sunday, February, 28th. The company reported ($0.05) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.02. The business earned $67.08 million during the quarter, compared to the consensus estimate of $60.84 million. Cardlytics had a negative net margin of 23.91% and a negative trailing twelve-month return on equity of 31.98%. The firm's quarterly revenue was down 3.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.18 EPS.
View Cardlytics' earnings history.

Cardlytics' stock was trading at $45.83 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CDLX stock has increased by 145.0% and is now trading at $112.30.
View which stocks have been most impacted by COVID-19.

Cardlytics updated its FY 2021 Pre-Market earnings guidance on Monday, March, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $250-275 million, compared to the consensus revenue estimate of $255.59 million.

6 brokerages have issued 12 month price targets for Cardlytics' shares. Their forecasts range from $75.00 to $150.00. On average, they anticipate Cardlytics' share price to reach $107.50 in the next twelve months. This suggests that the stock has a possible downside of 4.3%.
View analysts' price targets for Cardlytics or view top-rated stocks among Wall Street analysts.

63 employees have rated Cardlytics CEO Scott Grimes on Glassdoor.com. Scott Grimes has an approval rating of 86% among Cardlytics' employees.

Some companies that are related to Cardlytics include FactSet Research Systems (FDS), Weibo (WB), TripAdvisor (TRIP), OneConnect Financial Technology (OCFT), Dada Nexus (DADA), Chindata Group (CD), Rackspace Technology (RXT), Sabre (SABR), Medallia (MDLA), Magnite (MGNI), Switch (SWCH), 21Vianet Group (VNET), HUYA (HUYA), Pluralsight (PS) and Yalla Group (YALA).
View all of CDLX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardlytics investors own include NVIDIA (NVDA), Square (SQ), DocuSign (DOCU), Advanced Micro Devices (AMD), Caterpillar (CAT), The Walt Disney (DIS), Alibaba Group (BABA), The Trade Desk (TTD), QUALCOMM (QCOM) and Twilio (TWLO).

(CDLX) raised $76 million in an IPO on Friday, February 9th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."

Cardlytics' stock is owned by a number of retail and institutional investors. Top institutional investors include Calamos Advisors LLC (0.13%) and Acorn Financial Advisory Services Inc. ADV (0.04%). Company insiders that own Cardlytics stock include Aimia Inc, Andrew Christiansen, Bryce Youngren, Clifford Sosin, David Leslie Adams, David Thomas Evans, John L Jr Klinck, John V Balen, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Polaris Venture Management Co, Scott D Grimes and Tony Weisman.
View institutional ownership trends for Cardlytics.

CDLX stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, and Acorn Financial Advisory Services Inc. ADV. Company insiders that have sold Cardlytics company stock in the last year include Andrew Christiansen, Bryce Youngren, David Leslie Adams, David Thomas Evans, John L Jr Klinck, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Scott D Grimes, and Tony Weisman.
View insider buying and selling activity for Cardlytics or view top insider-selling stocks.

Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CDLX stock can currently be purchased for approximately $112.30.

Cardlytics has a market capitalization of $3.57 billion and generates $210.43 million in revenue each year. The company earns $-17,140,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

Cardlytics employs 486 workers across the globe.

The official website for Cardlytics is www.cardlytics.com.

Cardlytics is headquartered at 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308.

Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at (888) 798-5802 or via email at [email protected]